var data={"title":"Pantoprazole: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pantoprazole: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6721?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pantoprazole-drug-information\" class=\"drug drug_general\">see &quot;Pantoprazole: Drug information&quot;</a> and <a href=\"topic.htm?path=pantoprazole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pantoprazole: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50836901\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Proton Pump Inhibitors Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada has issued a safety alert regarding the rare risk of subacute cutaneous lupus erythematosus with the use of proton pump inhibitors (PPI). This alert was prompted following a published article that examined reports in the FDA Adverse Event Reporting System.</p>\n        <p style=\"text-indent:0em;\">Health Canada is working with manufacturers to update the safety information to include these findings in all PPI-containing products. More information may be found at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/proton-pump-inhibitors-assessing-risk-type-skin-reaction.html.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206239\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Protonix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206240\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Panto I.V.;</li>\n      <li>Pantoloc;</li>\n      <li>Tecta</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060918\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Gastric Acid Secretion Inhibitor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Proton Pump Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22152302\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>GERD, symptomatic:</b> Limited data available: Preterm (PMA &lt;44 weeks and weighing &ge;1.5 kg) and Term Neonates: Oral: 2.5 mg (~1.2 mg/kg/dose) once daily administered 30 minutes prior to first feeding of the day was evaluated in a pharmacokinetic trial in 21 neonatal patients (preterm: 19; term: 2; mean GA: 28 weeks; range: 23-41 weeks); this dose produced slightly higher systemic exposure than adolescents and adults receiving 40 mg, but there was no evidence of accumulation with repeated administration noted; although there was a significant increase in gastric pH and the amount of time the pH &gt;4, there was no significant difference in reflux episodes. A lower dose of 1.25 mg (0.6 mg/kg/dose) was also evaluated (n=19); however, this dose did not provide statistically significant improvements in pH-metry parameters (Kierkus, 2011; Ward, 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060911\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=pantoprazole-drug-information\" class=\"drug drug_general\">see &quot;Pantoprazole: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">\n      <b>Note:</b> Parenteral therapy should be discontinued as soon as the patient tolerates oral therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>GERD, symptomatic:</b> Limited data available: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;5 years: Oral: 1.2 mg/kg/day once daily for 4 weeks was shown to reduce GERD symptoms but was not significantly different from placebo (n=128; age range: 1 to 11 months) (Winter 2010); a pharmacokinetic trial showed this dose produced similar serum concentrations as adults receiving 40 mg in infants 1 to 11 months (mean age: 6.3 months) and slightly lower concentrations in children 1 to &lt;6 years (mean age: 3.2 years) (Tammara 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 5 to 11 years: Oral:  20 or 40 mg once daily have been shown  to reduce severity and frequency of symptoms within 1 week based on the GERD Assessment of Symptoms in Pediatric Patients Questionnaire (n=53, age range: 5 to 11 years); results also showed that while a lower dose of 10 mg  improved symptoms,  it took longer (3 weeks) for results (Tolia 2006); a pharmacokinetic trial in patients 6 to 11 years old (n=24) showed that  40 mg once daily produced similar systemic exposure as adults receiving 40 mg; however, the authors suggested that 20 mg once daily may be appropriate for small children (Ward 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents 12 to 16 years: Oral:  20 or 40 mg once daily was shown to reduce symptoms in patients with confirmed or clinically suspected diagnosis of GERD (n=136) based on the GERD Assessment of Symptoms in Pediatric Patients Questionnaire  (Tsou 2011); a pharmacokinetic trial showed that a 40 mg dose produced similar systemic exposure as adults receiving 40 mg; however, suggested that 20 mg once daily may be appropriate for smaller adolescents (&lt;40 kg) (Ward 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Erosive esophagitis associated with GERD:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 5 years: Limited data available: Oral: 0.3, 0.6, or 1.2 mg/kg/day once daily for 8 weeks was used in a dose-finding study of 60 patients with histologic or erosive esophagitis. High-dose treatment (1.2 mg/kg/day) was administered as a fixed dose of either: 15 mg for 1-year-olds <b>or</b> 20 mg for 2- to 5-year-olds. Patients with erosive esophagitis (n=4) received either 0.6 or 1.2 mg/kg/day.  All patients had symptomatic improvement and patients with erosive esophagitis were healed by week 8; no dose response relationship was demonstrated (Baker 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;5 years and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;15 to &lt;40 kg: 20 mg once daily for up to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;40 kg: 40 mg once daily for up to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Gastric acid suppression; oral therapy not appropriate or tolerated:</b> Limited data available; dosing regimens variable: Infants, Children, and Adolescents: IV: Dosing based on pharmacokinetic data from 39 pediatric patients (age range: 10 days to 16 years) which has shown doses within this range produce similar AUC as adult patients with comparable dosing; efficacy was not evaluated in either trial (Kearns 2008; Petersen 2009). </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Weight-based dosing: Children &ge;2 years and Adolescents: IV: 0.8 or 1.6 mg/kg once daily; maximum single dose: 80 mg; dosing from a single dose pharmacokinetic study in 18 patients (age range: 2 to 14 years) (Kearns 2008). In the BSA-based dosing trial (Petersen 2009), the final median dose when standardized to weight was 1.1 mg/kg/day (range: 0.5 to 4.6 mg/kg/day). (<b>Note:</b> The 4.6 mg/kg/day dose was a prescription error; however, the patient experienced no adverse consequences due to high dose). Additionally, some clinicians have used 1 to 2 mg/kg/day in single or divided doses. <b>Note:</b> In a very small trial (n=8), a median dose of 1.1 mg/kg (0.9 to 2.5 mg/kg) produced similar AUC values as adults, but only produced a definable response (gastric pH &gt;4) in one patient; in the remaining seven patients the mean percentage of time with intragastric pH &ge;4 was 7.4 % (Petersen 2005); the pharmacodynamic profile needs further defined (Petersen 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Body surface area (BSA)-based dosing: Infants, Children, and Adolescents: IV: 40 mg/1.73 m<sup>2</sup>/day; if inadequate response (eg, continued symptoms or target gastric pH not achieved) may titrate up to a maximum dose of 80 mg/1.73 m<sup>2</sup>/day; dosing based on multidose pharmacokinetic analysis; in the final analysis, the median reported dose was 41.8 mg/1.73 m<sup>2</sup>/day (range: 19.9-140.6 mg/1.73 m<sup>2</sup>/day) (<b>Note:</b> The 140.6 mg/1.73 m<sup>2</sup>/day dose was a prescription error; however, the patient experienced no adverse consequences due to high dose) (Petersen 2009).  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Erosive esophagitis associated with GERD:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Treatment: 40 mg once daily for up to 8 weeks; an additional 8 weeks may be used in patients who have not healed after an 8-week course</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Maintenance of healing: 40 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: 40 mg once daily for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Hypersecretory conditions (including Zollinger-Ellison syndrome):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: Initial: 40 mg twice daily; adjust dose based on patient response; doses up to 240 mg daily have been administered</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: Initial: 80 mg every 12 hours; adjust dosage to maintain acid output; 160-240 mg daily in divided doses has been used for a limited period (up to 7 days)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults: No dosage adjustment needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Hemodialysis: Not appreciably removed by hemodialysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults:  No dosage adjustment for doses up to 40 mg/day. Doses higher than 40 mg/day have not been studied in patients with hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206211\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Protonix: 40 mg (1 ea, 30 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Protonix: 40 mg (1 ea) [contains edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 40 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Protonix: 20 mg, 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg, 40 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206195\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15386979\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Protonix granules for oral suspension, delayed release tablets: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020987s053,022020s015lbl.pdf#page=30&amp;token=kJAC80Ianm2acD5sas7t+xUL6O3x65z6TVWP3ixDX9RvDDYAmyV1SzXePzEeerxzxtn34tPBLYuGo2RX8QOoBuAeyzqmiWKkkWPKhL/F1ligpyEGuKypq9RO67ovj3q5&amp;TOPIC_ID=12677\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020987s053,022020s015lbl.pdf#page=30</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060921\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: IV: Not for IM or SubQ use. Flush IV line with NS, D<sub>5</sub>W, or LR before and after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV push: Administer over 2 minutes at a concentration of 4 mg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intermittent IV infusion: Using a 0.4 to 0.8 mg/mL solution, infuse over 15 minutes at a rate not to exceed 7 mL/minute  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tablet: Should be swallowed whole; do not chew or crush. May be taken without regard to meals; however, best if taken 30 minutes before a meal (Lightdale 2013); may be administered with antacids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Delayed release oral suspension: Should only be administered in apple juice or applesauce and administered 30 minutes before a meal. Do not administer in water, other liquids, or foods. Per manufacturer's labeling, do not divide the 40 mg delayed release oral suspension packet to create a 20 mg dosage for pediatric patients who are unable to take the tablet formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral administration in apple juice: Empty intact granules into 5 mL of apple juice, stir for 5 seconds, and swallow immediately. Rinse container once or twice with apple juice and swallow immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral administration in applesauce: Sprinkle intact granules on 1 teaspoonful of applesauce; swallow within 10 minutes of preparation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Nasogastric tube administration: Separate the plunger from the barrel of a 60 mL catheter tip syringe and connect to a &ge;16 French nasogastric tube. Holding the syringe attached to the tubing as high as possible, empty granules into barrel of syringe, add 10 mL of apple juice, and gently tap/shake the barrel of the syringe to help empty the syringe. Add an additional 10 mL of apple juice and gently tap/shake the barrel to help rinse. Repeat rinse with at least 2 to 10 mL aliquots of apple juice. No granules should remain in the syringe.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral administration in syringe: In neonatal trials, fixed dosage packets of 2.5 mg pantoprazole were mixed with grape flavoring and 2.5 mL of water and administered immediately (Ward 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206232\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Store tablet and oral suspension at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Prior to reconstitution, store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not freeze. Protect from light prior to reconstitution; upon reconstitution, protection from light is not required. Do not freeze reconstituted solution. Per manufacturer's labeling, reconstituted solution is stable at room temperature for up to 6 hours; further diluted (admixed) solution in D5W, LR, or NS should be stored at room temperature and used within 24 hours from the time of initial reconstitution. However, studies have shown that reconstituted solution (4 mg/mL) in polypropylene syringes is stable up to 96 hours at room temperature (Johnson 2005). Upon further dilution, the admixed solution should be used within 96 hours from the time of initial reconstitution. The preparation should be stored at 3&deg;C to 5&deg;C (37&deg;F to 41&deg;F) if it is stored beyond 48 hours to minimize discoloration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060920\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Short-term treatment (up to 8 weeks) of erosive esophagitis associated with gastroesophageal reflux disease (GERD) (FDA approved in ages &ge;5 years and adults); maintenance of healing of erosive esophagitis (FDA approved in adults); treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome (FDA approved in adults); has also been used as adjunctive therapy of duodenal ulcers associated with <i>Helicobacter pylori  </i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Short-term treatment (7-10 days) of patients with GERD with a history of erosive esophagitis (FDA approved in adults); treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome (FDA approved in adults); has also been used as an alternative to oral therapy in patients who are unable to continue taking oral pantoprazole</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206294\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pantoprazole may be confused with ARIPiprazole</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Protonix may be confused with Lotronex, Lovenox, protamine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vials containing Protonix IV for injection are not recommended for use with spiked IV system adaptors. Nurses and pharmacists have reported breakage of the glass vials during attempts to connect spiked IV system adaptors, which may potentially result in injury to healthcare professionals.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Proton pump inhibitors are identified in the Beers Criteria as potentially inappropriate medications to be avoided (as scheduled use for more than 8 weeks) in patients 65 years and older due to its risk of <i>C. difficile</i> infection and bone loss/fractures. Use more than 8 weeks should be avoided unless given for high-risk patients (eg, oral corticosteroid or chronic NSAID use), patients with erosive esophagitis, Barrett's esophagitis, a pathological hypersecretory condition, or if the patient has demonstrated a need for maintenance therapy (eg, failure of drug discontinuation trial or failure of H<sup>2</sup> blockers) (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Protonix [US] may be confused with Pretanix brand name for indapamide [Hungary]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Protonix: Brand name for pantoprazole [US] but also the brand name for omeprazole [Phillipines]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206290\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">Cardiovascular: Edema, facial edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Depression, dizziness, headache, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin photosensitivity, skin rash (more common in children), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Increased serum triglycerides</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, constipation, diarrhea, flatulence, nausea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Leukopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Inflammation at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, increased creatine phosphokinase, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (more common in children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Ageusia, agranulocytosis, anaphylaxis (including anaphylactic shock), angioedema, bone fracture, <i>Clostridium difficile</i>-associated diarrhea, confusion, contact dermatitis, cutaneous lupus erythematous, decreased libido, diabetes mellitus, drowsiness, dysgeusia, ECG abnormality, eosinophilia, erythema multiforme, esophagitis, fatigue, gastric ulcer, gastrointestinal carcinoma, hallucination, hematuria, hepatic failure, hepatotoxicity (idiosyncratic) (Chalasani 2014), hyperbilirubinemia, hypertension, hypokinesia, hypomagnesemia, hyponatremia, impotence, increased appetite, increased serum alkaline phosphatase, interstitial nephritis, ischemic heart disease, jaundice, leukocytosis, malaise, neoplasm, nervousness, optic neuropathy (including anterior ischemic), pancreatitis, pancytopenia, paresthesia, pneumonia (Eom 2011), renal disease (chronic; Lazarus 2016), rhabdomyolysis, Stevens-Johnson syndrome, systemic lupus erythematosus, thrombosis, tinnitus, tongue discoloration, toxic epidermal necrolysis, tremor, visual disturbance, weakness, weight changes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206217\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, urticaria) to pantoprazole, other substituted benzimidazole proton pump inhibitors, or any component of the formulation; in combination with rilpivirine-containing products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concomitant use with rilpivirine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206199\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Carcinoma: Benign and malignant neoplasia has been observed in long-term (2-year) rodent studies; while not reported in humans, the relevance of these findings in regards to tumorigenicity in humans is not known.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; <i>Clostridium difficile</i>-associated diarrhea (CDAD): Use of proton pump inhibitors (PPIs) may increase risk of CDAD, especially in hospitalized patients; consider CDAD diagnosis in patients with persistent diarrhea that does not improve. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous and systemic lupus erythematosus: Has been reported as new onset or exacerbation of existing autoimmune disease; most cases were cutaneous lupus erythematosus (CLE), most commonly, subacute CLE (occurring within weeks to years after continuous therapy). Systemic lupus erythematosus (SLE) is less common (typically occurs within days to years after initiating treatment) and occurred primarily in young adults up to elderly patients. Discontinue therapy if signs or symptoms of CLE or SLE occur and refer to specialist for evaluation; most patients improve 4 to 12 weeks after discontinuation of pantoprazole.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fractures: Increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy. Patients on high-dose or long-term therapy (&ge;1 year) should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI infection (eg, <i>Salmonella, Campylobacter</i>): Use of PPIs may increase risk of these infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Mild, transient transaminase elevations have been observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypomagnesemia: Reported rarely, usually with prolonged PPI use of &ge;3 months (most cases &gt;1 year of therapy). May be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter. Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of pantoprazole may be necessary; magnesium levels typically return to normal within 2 weeks of stopping.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion-related reactions: Thrombophlebitis and serious hypersensitivity reactions, including anaphylaxis, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported with IV administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Interstitial nephritis: Acute interstitial nephritis has been observed in patients taking PPIs; may occur at any time during therapy and is generally due to an idiopathic hypersensitivity reaction. Discontinue if acute interstitial nephritis develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vitamin B<sub>12</sub> deficiency: Prolonged treatment (&ge;2 years) may lead to vitamin B<sub>12</sub> malabsorption and subsequent vitamin B<sub>12</sub> deficiency. The magnitude of the deficiency is dose-related and the association is stronger in females and those younger in age (&lt;30 years); prevalence is decreased after discontinuation of therapy (Lam 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel. Of the PPIs, pantoprazole has the lowest degree of CYP2C19 inhibition <i>in vitro</i> (Li 2004) and has been shown to have less effect on conversion of clopidogrel to its active metabolite compared to omeprazole (Angiolillo 2011). In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel (Abraham 2010, Levine 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Edetate sodium (EDTA): Some dosage forms may contain edetate sodium; use caution in patients who are at risk for zinc deficiency if other EDTA-containing solutions are coadministered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <i>Helicobacter pylori</i> eradication: Short-term combination therapy (&le;7 days) has been associated with a higher incidence of treatment failure. The American College of Gastroenterology recommends 10 to 14 days of therapy (triple or quadruple) for eradication of <i>H. pylori</i> (Chey 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206277\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (major), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BCRP/ABCG2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206204\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12677&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: Proton Pump Inhibitors may decrease the serum concentration of Acalabrutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamine: Proton Pump Inhibitors may increase the absorption of Amphetamine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capecitabine: Proton Pump Inhibitors may diminish the therapeutic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefpodoxime: Proton Pump Inhibitors may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefuroxime: Proton Pump Inhibitors may decrease the absorption of Cefuroxime. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: Pantoprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Due to the possible risk for impaired clopidogrel effectiveness, clinicians should carefully consider the need for proton pump inhibitor therapy in patients receiving clopidogrel.  Other acid-lowering therapies do not appear to share this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cysteamine (Systemic): Proton Pump Inhibitors may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C19 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: Proton Pump Inhibitors may decrease the serum concentration of Dabrafenib. Dabrafenib may decrease the serum concentration of Proton Pump Inhibitors.  Management: Seek alternatives to the proton pump inhibitor when possible.  If concomitant therapy cannot be avoided, monitor for diminished effects of both drugs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dextroamphetamine: Proton Pump Inhibitors may increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Conversely, concentrations of active metabolites may be increased for those drugs activated by CYP2C19. Management: Concurrent use of enzalutamide with CYP2C19 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP2C19 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.  Management: Avoid use of proton pump inhibitors (PPIs) with gefitinib when possible. If required, administer gefitinib 12 hours after administration of the PPI or 12 hours before the next dose of the PPI.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Citrate; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: Proton Pump Inhibitors may decrease the serum concentration of Ledipasvir.  Management: PPI doses equivalent to omeprazole 20 mg or lower may be given with ledipasvir under fasted conditions. Administration with higher doses of PPIs, 2 hours after a PPI, or in combination with food and PPIs may reduce ledipasvir bioavailability.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: Proton Pump Inhibitors may decrease the serum concentration of Neratinib. Specifically, proton pump inhibitors may reduce neratinib absorption. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: Proton Pump Inhibitors may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Proton Pump Inhibitors may decrease the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Proton Pump Inhibitors may diminish the diagnostic effect of Secretin. Specifically, use of PPIs may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of proton pump inhibitors (PPIs) and secretin, and discontinue PPIs several weeks prior to secretin administration, with the duration of separation determined by the specific PPI. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: Proton Pump Inhibitors may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Proton Pump Inhibitors. Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24794079\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Prolonged treatment (&ge;2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206207\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206220\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Most available studies have not shown an increased risk of major birth defects following maternal use of proton pump inhibitors during pregnancy (Diav-Citrin 2005; Erichsen 2012; Matok 2012; Pasternak 2010). When treating GERD in pregnancy, PPIs may be used when clinically indicated (Katz 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206198\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Proton pump inhibitor, suppresses gastric acid secretion by inhibiting the parietal cell H<sup>+</sup>/K<sup>+</sup> ATP pump</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206216\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Pediatric patients who have the poor metabolizer genotype of CYP2C19 (CYP2C19 *2/*2) exhibited greater than a 6-fold increase in AUC compared with pediatric extensive (CYP2C19 *1/*1) and intermediate (CYP2C19 *1/*x) metabolizers. Poor metabolizers exhibited approximately 10-fold lower apparent oral clearance compared with extensive metabolizers.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Acid secretion: Oral: 2.5 hours; IV: 15 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maximum effect: IV: 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid, well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Oral, IV: 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents (Kearns 2008): IV (2 to 16 years of age): 0.22 &plusmn; 0.14 L/kg; Oral (5 to 16 years of age): 0.24 &plusmn; 0.09 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 11 to 23.6 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 98%, primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic; CYP2C19 (demethylation), CYP3A4; no evidence that metabolites have pharmacologic activity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: ~77%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates (PMA: 37 to 44 weeks): ~3 hours (Ward 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents (Kearns 2008): IV (2 to 16 years of age): 1.22 &plusmn; 0.68 hours; Oral (5 to 16 years of age): 1.27 &plusmn; 1.29 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 1 hour; increased to 3.5 to 10 hours with CYP2C19 deficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents (Kearns 2008): IV (2 to 16 years of age): 0.34 &plusmn; 0.12 hours; Oral (5 to 16 years of age): 2.54 &plusmn; 0.72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Oral: 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (71% as metabolites); feces (18%); pantoprazole clearance increased with weight and age (Pettersen 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206215\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 2 mg/mL pantoprazole oral suspension may be made with pantoprazole tablets, sterile water, and sodium bicarbonate powder. Remove the Protonix&reg; imprint from twenty 40 mg tablets with a paper towel dampened with ethanol (improves the look of product). Let tablets air dry. Crush the tablets in a mortar and reduce to a fine powder. Transfer to a 600 mL beaker, and add 340 mL sterile water. Place beaker on a magnetic stirrer. Add 16.8 g of sodium bicarbonate powder and stir for about 20 minutes until the tablet remnants have disintegrated. While stirring, add another 16.8 g of sodium bicarbonate powder and stir for about 5 minutes until powder has dissolved. Add enough sterile water for irrigation to bring the final volume to 400 mL. Mix well. Transfer to amber-colored bottle. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 62 days refrigerated.</p>\n    <div class=\"reference\">Dentinger PJ, Swenson CF, and Anaizi NH, &ldquo;Stability of Pantoprazole in an Extemporaneously Compounded Oral Liquid,&rdquo; <i>Am J Health Syst Pharm</i>, 2002, 59(10):953-6.<span class=\"pubmed-id\">12040734</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206219\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Protonix Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (1): $17.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Pantoprazole Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (1): $8.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Protonix Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (1): $6.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Pantoprazole Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $368.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (90): $368.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Protonix Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $1,549.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (90): $1,549.58</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206223\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acernix (PH);</li>\n      <li>Acipan (HR, SI);</li>\n      <li>Alapanzol (ES);</li>\n      <li>Alpanzole (SG);</li>\n      <li>Altana (PH);</li>\n      <li>Anagastra (ES);</li>\n      <li>Anxel (EE);</li>\n      <li>Apton (PT);</li>\n      <li>Axepron (PH);</li>\n      <li>Azatol (RO);</li>\n      <li>Azidex (AT);</li>\n      <li>Bio-Panto (VN);</li>\n      <li>Branzol (UY);</li>\n      <li>Ciproton (MX);</li>\n      <li>Conpanzole (MY);</li>\n      <li>Controloc (BG, CZ, EE, EG, HR, HU, IL, IR, JO, LT, LV, MT, MY, PK, PL, RO, RU, SE, SG, SI, SK, TH, ZA);</li>\n      <li>Eumac (IN);</li>\n      <li>Eupantol (FR);</li>\n      <li>Fozole (IN);</li>\n      <li>Gastenz (AU);</li>\n      <li>Gastroloc (TW);</li>\n      <li>Gastromax (AR);</li>\n      <li>Inipomp (FR);</li>\n      <li>Ipraalox (LU, LV);</li>\n      <li>Kaiji (CN);</li>\n      <li>Kontrolok (UA);</li>\n      <li>Kuppam (MX);</li>\n      <li>Leminter (MX);</li>\n      <li>Luoxu (CN);</li>\n      <li>Mefogin (VN);</li>\n      <li>Nixpan (BD);</li>\n      <li>Noacid (BG);</li>\n      <li>Nocid (PH);</li>\n      <li>Nolpaza (EE, LV, MY, SK);</li>\n      <li>Ottozol (ID);</li>\n      <li>Ozpan (AU);</li>\n      <li>Pandecta (ID);</li>\n      <li>Panfred (LK);</li>\n      <li>Panloc (ID);</li>\n      <li>Panoz (BD);</li>\n      <li>Panprax (CH);</li>\n      <li>Panrazol (HK);</li>\n      <li>Pantazol (PH);</li>\n      <li>Pantec (IN);</li>\n      <li>Pantecta (CR, DO, ES, GT, HN, IT, MT, NI, NL, PA, SV);</li>\n      <li>Panteon (KR);</li>\n      <li>Pantex (BD);</li>\n      <li>Pantin (SG);</li>\n      <li>Panto (TR);</li>\n      <li>Panto-Byk (LU);</li>\n      <li>Pantoavenir IV (IL);</li>\n      <li>Pantoc (PT);</li>\n      <li>Pantocar (LK, PH);</li>\n      <li>Pantocid (NZ, TH, ZA);</li>\n      <li>Pantodac (IN);</li>\n      <li>Pantodar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Pantol (LV);</li>\n      <li>Pantoline (KR);</li>\n      <li>Pantoloc (AT, CN, DK, EG, ES, FR, HK, JO, KR, LT, PH, QA, SE, TW, TZ, VN);</li>\n      <li>Pantomax (QA);</li>\n      <li>Pantomed (KR);</li>\n      <li>Pantop (AR, PK, VE);</li>\n      <li>Pantopan (IN, IT);</li>\n      <li>Pantoprix (PH);</li>\n      <li>Pantoprol (TH);</li>\n      <li>Pantopump (ID);</li>\n      <li>Pantor (PH);</li>\n      <li>Pantostac (KR);</li>\n      <li>Pantostad (HK);</li>\n      <li>Pantover (QA);</li>\n      <li>Pantoz (LK);</li>\n      <li>Pantozol (AE, AT, BE, BH, CH, CY, DE, EG, ID, IQ, IR, JO, KW, LB, LU, LY, MT, MX, NL, OM, PH, QA, SA, SE, SY, YE);</li>\n      <li>Pantul (EE);</li>\n      <li>Panum (UA);</li>\n      <li>Panzol (BD, UA);</li>\n      <li>Panzole (MY, SG);</li>\n      <li>Panzomex (ID);</li>\n      <li>Panzor (FI);</li>\n      <li>Pauly (MX);</li>\n      <li>Pentowin (HK);</li>\n      <li>Peptazol (AR, MY, SG);</li>\n      <li>Peptazole (HK);</li>\n      <li>Pepticus (PY);</li>\n      <li>Pepzol (ID);</li>\n      <li>Peucetol (MX);</li>\n      <li>Pozola (TW);</li>\n      <li>Prompin (LK);</li>\n      <li>Protium (GB, IE);</li>\n      <li>Protocid (BD);</li>\n      <li>Proton (QA);</li>\n      <li>Protopan (PY);</li>\n      <li>Prozolan (MX);</li>\n      <li>Pulcet (BG);</li>\n      <li>Razon (LB);</li>\n      <li>Regad (MX);</li>\n      <li>Rifun 40 (DE);</li>\n      <li>Salpraz (AU);</li>\n      <li>Segregam (CO);</li>\n      <li>Somac (AU, CZ, FI, NO, NZ);</li>\n      <li>Sozol (AU, VN);</li>\n      <li>Stripole (TH);</li>\n      <li>Sunpraz (RU);</li>\n      <li>Tecta (CO, CR, DO, EC, GT, HN, MX, NI, PA, SV);</li>\n      <li>Tonval (PE);</li>\n      <li>Topazol (ID);</li>\n      <li>Toprazol (KR);</li>\n      <li>Toprazole (ET, MY);</li>\n      <li>Trupan (LK);</li>\n      <li>Ulcemex (CL, PY);</li>\n      <li>Ulcoreks (ET);</li>\n      <li>Ulprix (BG);</li>\n      <li>Unigastrozol (MX);</li>\n      <li>Vencid (MY);</li>\n      <li>Vomizole (ID);</li>\n      <li>Xotepic (PL);</li>\n      <li>Zolpra (MX);</li>\n      <li>Zoltum (CR, DO, EC, GT, HN, NI, PA, PE, SV);</li>\n      <li>Zurcal (AT, BR, CH, CL, CO, EC, MX, PE, PT);</li>\n      <li>Zurcale (BE);</li>\n      <li>Zurcamed (BE);</li>\n      <li>Zurcazol (GR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abraham NS, Hlatky MA, Antman EM, et al, &quot;CCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,&quot; <i>Circulation</i>, 2010, 122(24):2619-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/21060077/pubmed\" target=\"_blank\" id=\"21060077\">21060077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Angiolillo DJ, Gibson CM, Cheng S, et al, &quot;Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies,&quot; <i>Clin Pharmacol Ther</i>, 2011, 89(1):65-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/20844485/pubmed\" target=\"_blank\" id=\"20844485\">20844485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baker R, Tsou VM, Tung J, et al, &quot;Clinical Results From a Randomized, Double-Blind, Dose-Ranging Study of Pantoprazole in Children Aged 1 Through 5 Years With Symptomatic Histologic or Erosive Esophagitis,&quot; <i>Clin Pediatr (Phila)</i>, 2010, 49(9):852-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/20522615/pubmed\" target=\"_blank\" id=\"20522615\">20522615</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canani RB, Cirillo P, Roggero P, et al, &quot;Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children,&quot; <i>Pediatrics</i>, 2006, 117(5):e817-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/16651285/pubmed\" target=\"_blank\" id=\"16651285\">16651285</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD, Wong BC, et al, &ldquo;American College of Gastroenterology Guideline on the Management of <i>Helicobacter pylori</i> Infection,&rdquo; <i>Am J Gastroent</i>, 2007, 102(8):1808-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/17608775/pubmed\" target=\"_blank\" id=\"17608775\">17608775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diav-Citrin O, Arnon J, Shechtman S, et al, &quot;The Safety of Proton Pump Inhibitors in Pregnancy: A Multicentre Prospective Controlled Study,&quot; <i>Aliment Pharmacol Ther</i>, 2005, 21(3):269-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/15691301/pubmed\" target=\"_blank\" id=\"15691301\">15691301</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erichsen R, Mikkelsen E, Pedersen L, et al, &quot;Maternal Use of Proton Pump Inhibitors During Early Pregnancy and the Prevalence of Hypospadias in Male Offspring,&quot; <i>Am J Ther</i>, 2012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/22314213/pubmed\" target=\"_blank\" id=\"22314213\">22314213</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson CE, &quot;Stability of Pantoprazole in 0.9% Sodium Chloride Injection in Polypropylene Syringes,&quot; <i>Am J Health Syst Pharm</i>, 2005, 62(22):2410-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/16278334/pubmed\" target=\"_blank\" id=\"16278334\">16278334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n     Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katz PO, Gerson LB, and Vela MF, &quot;Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease,&quot; <i>Am J Gastroenterol</i>, 2013, 108(3):308-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/23419381/pubmed\" target=\"_blank\" id=\"23419381\">23419381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearns GL, Blumer J, Schexnayder S, et al, &quot;Single-Dose Pharmacokinetics of Oral and Intravenous Pantoprazole in Children and Adolescents,&quot; <i>J Clin Pharmacol</i>, 2008, 48(11):1356-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/18664620/pubmed\" target=\"_blank\" id=\"18664620\">18664620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kierkus J, Furmaga-Jablonska W, Sullivan JE, et al. Pharmacodynamics and safety of pantroprazole in neonates, preterm infants, and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease. <i>Dig Dis Sci</i>. 2011;56:425-434. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/20607405/pubmed\" target=\"_blank\" id=\"20607405\">20607405</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/24327038/pubmed\" target=\"_blank\" id=\"24327038\">24327038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &quot;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&quot; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lightdale JR, Gremse DA, and the Section on Gastroenterology, Hepatology, and Nutrition,&quot; Gastroesophageal Reflux: Management Guidance for the Pediatrician,&quot; <i>Pediatrics</i>, 2013, 131(5):e1684-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/23629618/pubmed\" target=\"_blank\" id=\"23629618\">23629618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li XQ, Andersson TB, Ahlstr&ouml;m M, et al, &quot;Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,&quot; <i>Drug Metab Dispos</i>, 2004, 32(8):821-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/15258107/pubmed\" target=\"_blank\" id=\"15258107\">15258107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Madrazo-De La Garza A, Dibildox M, Vargas A, et al, &ldquo;Efficacy and Safety of Oral Pantoprazole 20 mg Given Once Daily for Reflux Esophagitis in Children,&rdquo; <i>J Pediatr Gastroenterol Nutr</i>, 2003, 36(2):261-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/ 12548064 /pubmed\" target=\"_blank\" id=\" 12548064 \"> 12548064 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matok I, Levy A, Wiznitzer A, et al, &quot;The Safety of Fetal Exposure to Proton-Pump Inhibitors During Pregnancy,&quot; <i>Dig Dis Sci</i>, 2012, 57(3):699-705.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/22038541/pubmed\" target=\"_blank\" id=\"22038541\">22038541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pasternak B and Hviid A, &quot;Use of Proton-Pump Inhibitors in Early Pregnancy and the Risk of Birth Defects,&quot; <i>N Engl J Med</i>, 2010, 363(22):2114-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/21105793/pubmed\" target=\"_blank\" id=\"21105793\">21105793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Petterson G, Faure C, Litalien C, et al. Therapeutic failure of a single intravenous dose of pantoprazole in young intensive care children. <i>Crit Care Med</i>. 2005;33(12): A170.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pettersen G, Mouksassi MS, Theoret Y, et al. Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. <i>Br J Clin Pharmacol</i>. 2009;67(2):216-227.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/19173681/pubmed\" target=\"_blank\" id=\"19173681\">19173681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plante L, Ferron GM, Unruh M, et al, &quot;Excretion of Pantoprazole in Human Breast,&quot; <i>J Reprod Med</i>, 2004, 49(10):825-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/15568407/pubmed\" target=\"_blank\" id=\"15568407\">15568407</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tammara BK, Sullivan JE, Adcock KG, et al, &quot;Randomized, Open-Label, Multicentre Pharmacokinetic Studies of Two Dose Levels of Pantoprazole Granules in Infants and Children Aged 1 Month Through &lt;6 Years With Gastro-oesophageal Reflux Disease,&quot; <i>Clin Pharmacokinet</i>, 2011, 50(8):541-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/21740077/pubmed\" target=\"_blank\" id=\"21740077\">21740077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tolia V, Bishop PR, Tsou VM, et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with sympomatic gastroesophageal reflux disease. <i>JPGN</i>. 2006;42:384-391.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/16641576/pubmed\" target=\"_blank\" id=\"16641576\">16641576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tsou VM, Baker R, Book L, et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). <i>Clin Pediatr</i>. 2006;45:741-749.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/16968960/pubmed\" target=\"_blank\" id=\"16968960\">16968960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ward RM, Kearns GL, Tammara B, et al. A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with GERD. <i>J Clin Pharmacol</i>. 2011;51(6):876-887.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/20852004/pubmed\" target=\"_blank\" id=\"20852004\">20852004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ward RM, Tammara B, Sullivan SE, et al. Single-dose, multiple-dose, and population pharmacokinetics of pantroprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). <i>Eur J Clin Pharmacol</i>. 2010;66:555-561.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/20306184/pubmed\" target=\"_blank\" id=\"20306184\">20306184</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winter H, Kum-Nji P, Mahomedy SH, et al, &quot;Efficacy and Safety of Pantoprazole Delayed-Release Granules for Oral Suspension in a Placebo-Controlled Treatment-Withdrawal Study in Infants 1-11 Months Old With Symptomatic GERD,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2010, 50(6):609-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pantoprazole-pediatric-drug-information/abstract-text/20400912/pubmed\" target=\"_blank\" id=\"20400912\">20400912</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12677 Version 242.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50836901\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F206239\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F206240\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060918\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F22152302\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060911\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F206211\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F206195\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F15386979\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060921\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F206232\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060920\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F206294\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F206290\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F206217\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F206199\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F206277\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F206204\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F24794079\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F206207\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F206220\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F206198\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F206216\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F206215\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F206219\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F206223\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12677|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pantoprazole-drug-information\" class=\"drug drug_general\">Pantoprazole: Drug information</a></li><li><a href=\"topic.htm?path=pantoprazole-patient-drug-information\" class=\"drug drug_patient\">Pantoprazole: Patient drug information</a></li></ul></div></div>","javascript":null}